Guangzhou and London – May 22, 2025 – Bio-Thera Solutions,Ltd (688177:SH), a commercial-stage biopharmaceutical company developing apipeline of biosesimilars and innovative assets and Hikma Pharmaceuticals PLC,along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announcedtha...
DetailsGuangzhou – July 16, 2025 – Bio-Thera Solutions, Ltd (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline of biosesimilars and innovative todayannounced that the U.S. Food and Drug Administration (FDA) has accepted itsBiologics License Application (BLA) for BAT2506, a pro...
Guangzhou,China – July 2025 – Bio-Thera Solutions, Inc. (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies andbiosesimilars, today announced that the Independent Data Monitoring Committee(IDMC) has recommended early study termination for the pivo...
Guangzhou, China– June 25, 2025 – Bio-TheraSolutions Inc. (688177:SH), acommercial-stage biopharmaceutical company developing a pipeline of innovativetherapies and biosesimilars, today announced that dosing has begun in a phase 3clinical study for BAT8006, an antibody drug conjugate targeting fola...
